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(U-14,624) with Metalloproteins and Its Potential for 
Undergoing Phase II Metabolism (80 pp.)
Director: Jerry R. Smith, Ph.D.
Rats and rabbits were used to study the effects of U-
14,624, on three metalloproteins (angiotensin converting 
enzyme (ACE), pseudocholinesterase and thyroid peroxidase 
enzyme - reflected by thyroxine levels) in vivo with the 
assays done in vitro.
U-14,624 (100 mg/kg i.p.) caused a decline in pseudoch- 
olinesterase activity between 6 and 18 hours. The most 
pronounced decrease in pseudocholinesterase activity was 
observed at 12 hours. The effect of U-14,624 on pseudocholi- 
nesterase activity levelled off at doses in excess of 75 
mg/kg 12 hours post treatment. While acute doses of U-14,624 
(50 - 200 mg/kg i.p.) did not have any effect on ACE 
activity, chronic dosing of U-14,624 (50 mg/kg/day , i.p.) 
had a pronounced effect on ACE activity. Acute doses of U-
14,624 (100 mg/kg i.p.) prominently suppressed thyroxine 
levels within 4 days. Chronic dosing of U-14,624 (50 
mg/kg/day, i.p.) drastically suppressed thyroxine levels 
within 7 days. Drug administration was terminated on day 7 
due to toxicity evidenced by 16% and 31% drops in KBW of 
rabbits.
The second phase of this work sought to determine the 
potential metabolic pathways available for U-14,624 
metabolism. Rats treated with U-14,624 (100 mg/kg i.p.) 
showed a decrease in their serum sulfate levels over the 
course of 6 to 18 hours. The maximal depletion of sulfate 
was observed at 12 hours. A dose-dependent decrease in serum 
sulfate which levelled off at doses of U-14,624 exceeding 75 
mg/kg was observed at 12 hours post drug administration. A 
significant difference was observed in the amount of 
conjugated glucuronides between U-14,624 and control urine, 
but no significant difference was observed either between 
the solvent and U-14,624 treated urine or between the con­
trol and solvent treated urine.
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CHAPTER 1
INTRODUCTION
Background:
1-Phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624) was 
synthesized by Uno (1960) from 2-aminothiazole and phenyl- 
isothiocyanate. U-14,624 was expected to function as a 
sensitive indicator of heavy metal ions by forming colored 
chelates. Subsequently, U-14,624 was shown to form colored 
chelates (in their decreasing order of sensitivity) with 
Cu^ > Ni^ = Pd^ = Ag^ > Hg^ > Pb^ = A u ^  > Bi*++ > Pt^.
These metals formed colored chelates with U-14,624 at a 
concentration of 0.2 to 10 ug/ml.
Based on the work of Johnson et al (1969) and Von 
Voigtlander and Moore (1970), U-14,624 is currently 
classified as an inhibitor of the enzyme dopamine bsia- 
hydroxylase (DBH). U-14,624 exerts its effect by chelating 
the copper ions of the enzyme. The inhibition of DBH by U-
14,624 has been shown to correlate with the depletion of 
central norepinephrine (NE) levels and increased dopamine 
(DA) levels (Johnson et al, 1969; von voigtlander and Moore, 
1970; Johnson et al, 1970; Wise et al, 1977; Thornburg and 
Moore, 1971).
Catecholamines (Dopamine, Norepinephrine (NE) and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Epinephrine) are synthesized from the amino acid tyrosine. 
The synthesis of catecholamines was first proposed by 
Blachko (1939) to involve a sequence of enzymatic steps.
Tyrosine hydroxylase is the first enzyme in the 
biosynthetic pathway of catecholamines. It catalysis the 
conversion of tyrosine to dihydroxyphenylalanine (DOPA) in 
the axoplasm of neurons. Tyrosine hydroxylase is a mixed 
function oxidase, that requires molecular oxygen, ferrous 
ions and a cofactor, tetrahydropteridiene, for optimal 
activity (Cooper et al, 1982). This conversion of tyrosine 
to dopa is the rate-limiting step in catecholamine 
biosynthesis, and is therefore, subject to end-product 
inhibition (Weiner et al, 1972; Weiner, 1979).
Dopa is converted to dopamine by dopa decarboxylase. This 
enzyme is also known as an L-amino acid decarboxylase 
because of its nonspecific action (Cooper et al, 1982). It 
can act on all L-amino a cids. Dopamine is transported into 
the granulated vesicles where it is converted to NE by 
dopamine beta-hydroxylase (DBH). DBH is a copper containing 
enzyme and also a mixed function oxidase, that requires 
molecular oxygen and ascorbic acid as a cofactor for optimal 
activity (Cooper et al, 1982).
In the adrenal medulla, NE is N-methylated by 
phenylethanolamine N-methyltransferase (PNMT) to form 
epinephrine (Goldstein et al, 1972). PNMT requires the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
presence of a methyl donor, S-adenosylmethionine (SAM), for 
its activity.
Joh et al (1984) have shown that these enzymes, tyrosine 
hydroxylase, DBH and PNMT, could be under a common genetic 
control. They appear to have a homologous sequence of amino 
acid. None of these enzymes is highly specific in activity. 
Therefore, they could act on other endogenous and exogenous 
substances (Baker et al, 1972). In addition, tyrosine 
hydroxylase and DBH are also subject to inhibition by 
exogenous compounds. Tyrosine hydroxylase can be inhibited 
by amino acid analogs (alpha-methyl-p-tyrosine (AMT), 3- 
iodotyrosine or a1pha-methyl-5-hydroxytryptophan), catechol 
derivatives, tropolones and selective iron chelators (Cooper 
et al, 1982). Similarly, DBH can be inhibited by a variety 
of compounds . The most effective inhibitors are those 
compounds that chelate copper ions. Diethyldiothiocarbamate 
(DDC), a metabolite of disulfiram, and b is-(l-methyl-4- 
homopiperazinyl thiocarbonyl)-disulfide (FLA-6 3) are 
effective inhibitors of DBH both in vivo and JLu vitro 
(Corrodi et al, 1970; Friedman and Kaufman, 1965).
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LITERATURE REVIEW
Activities of U-14,624 and effec-ts resulting from its
5i6̂2J[3LtJtZi2LJLiiw.JlhJDhJbLiLJt2LïLiLi3»̂2dQ̂ £̂LÎ̂ —̂
U-14,624 has been shown to be the most potent inhibitor 
of DBH with the exception of disulfiram (Johnson et al, 
1969). DBH inhibition was dependent on the length of 
preincubation with the inhibitor. Incubation for 5 minutes 
with U-14,624 resulted in competitive inhibition while 
incubation for 15 minutes resulted in non-competitive 
inhibition. It was concluded that this type of inhibition 
(mixed inhibition) may be due to: a), the competition of
the inhibitor and substrate for the active site of the 
enzyme (competitive inhibition) and b ) . a slowly reversible 
interaction of the sulfur of U-14,624 with the copper of DBH 
(non-competitive inhibition).
In their study of central catecholamine modifications by 
U-14,624 ( 25 to 200 mg/kg i.p.), Johnson et al (1969), Von 
Voigtlander and Moore (1970) and Johnson et al (1970) have 
observed that mice are more resistant than rats towards the 
central effect of U-14,624. Low doses of U-14,624 (25 mg/kg 
i.p.) decreased brain NE levels in both species with an 
increase in DA. The effect was more pronounced in the rats. 
Central levels of NE were lowered to less than 10% of 
control by a single dose of U-14,624 at 200 mg/kg i.p. while
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
the central levels of NE in mice treated with the same dose 
rarely fell below 20% of control levels. The rats were also 
slower in their recovery rate than the mice. NE levels 
depleted by a single dose of U-14,624 (200 mg/kg i.p.) had 
recovered to only 60% of control after 48 hours in the rats 
while the mice were completely recovered in 48 hours, it was 
observed that an increase in DA level occurred in the mouse 
and rats at doses of U-14,624 in excess of 100 mg/kg i.p. 
and 25 mg/kg i.p., respectively. The increase in DA levels 
remained elevated for 12 hours in rats (Johnson et al, 1970} 
whereas the increase in DA levels in mice was short term and 
remained elevated for about 4 hours (Johnson et al, 1970 
and Von Voigtlander and Moore, 1970). Johnson et al (1972) 
have observed that the decrease in central NE levels after a 
single dose of U-14,624 (200 mg/kg i.p.) was accompanied by 
a simultaneous increase in central levels of 5-hydroxy- 
indoleacetic acid (5-HIAA) and 5-hydroxytryptamine (5-HT). 
Brain 5-HT levels began increasing after a dormant period of 
2 to 3 hours at which time 5-HlAA levels had increased by 
50% of control.
Von Voigtlander and Moore (1970) have shown that a single 
dose of U-14,624 (100 mg/kg i.p.) in mice resulted in a 
prompt and sustained depression of spontaneous locomotor 
activity (SLMA). This effect was accompanied by a 
significant decrease in the central NE level and an increase
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
in DA levels, it was observed that the reduction in SLMA and 
NE levels may not be causally related, while 100 mg/kg i.p. 
and 200 mg/kg po of U-14,624 produced equivalent depletion 
of NE levels, they caused 80% and 30% reductions in SLMA, 
respectively, voigtlander and Moore then proposed that SLMA 
may not be the best method of studying the depressant 
properties of U-14,624, but rather conditioned avoidance 
response (CAR) would be the preferred method. The latter 
test is generally less affected by peritoneal irritation 
than SLMA. The greater suppression of SLMA observed 
subsequent to intraperitoneal (i.p.) administration could 
result from peritoneal irritation caused by U-14,624, an 
insoluble drug. Thornburg and Moore (1971) not only observed 
the suppression in SLMA and NE levels with U-14,624, but 
also observed 100%-200% increase in corticosterone and blood 
glucose levels. It was proposed that the elevated level of 
corticosterone may be due to the irritation of the 
peritoneal cavity by the drug particles. Furthermore, they 
suggested that the increase in blood glucose could be due 
to U-14,624 effects on carbohydrate metabolism in addition 
to those resulting from the general irritant properties of 
the compound.
Evidence has accumulated showing that U-14,624 does 
interact with the central alpha-adrenergic receptors. Kalara 
et al (1972) have demonstrated that U-14,624 (200 mg/kg
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
i.p.) blocks progesterone-induced release of gonadotropins 
(luteinizing hormone, LH and follicle stimulating hormone, 
FSH) in ovariectomized rats, probably by suppressing levels 
of NE, a neurotransmitter, at the preoptic area of the 
hypothalamus. They proposed that NE is the mediator which 
mediates the stimulatory effect of progesterone on the 
release of gonadotropins. The administration of DL-threo- 
dihydroxyphenyl-serine (DOPS), which is converted to NE by 
L-aromatic amino acid decarboxylase, was effective in 
reversing the effects of u-14,624, but the administration of 
L-dihydroxyphenylalanine (DOPA) was ineffective. It was 
observed that the alpha-adrenergic blocking agent 
phenoxybenzamine did inhibit the progesterone-induced 
release of gonadotropin. In addition, Bha ttacha raya et al 
(1972) have observed a similar phenomenon with U-14,624 in 
ovariectomized rhesus monkey. Using phenoxybenzamine and 
phentolamine, alpha-adrenergic blockers, progesterone- 
induced release of gonadotropin was not inhibited. Drouva 
and Gallo (1976) have shown that U-14,624 (200 mg/kg i.p.) 
caused a 90% reduction in hypothalamic NE levels 18 hours 
post drug administration while at the same time inhibiting 
the episodic secretion of LH. Kohn et al (1982) have 
confirmed the previous findings in ovariectomized rats. They 
observed that U-14,624 at the same dose caused a significant 
decrease in the mediobasal hypothalamus (MBH) NE levels and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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plasma levels of gonadotropin with an increase in DA levels. 
The suppression of the MBH NE levels and gonadotropin 
concentrations were observed to last at least 12-48 hours.
Using a steroid-dependent behavior that is influenced by 
noradrenergic transmission to test if steroid action 
within the brain is modulated by neutrotransmiters, Nock et 
al (1981) observed that female guinea pigs, primed with 
estradiol-17 beta benzoate (EB) 34 hours before U-14,624 
(150 mg/kg i.p.) administration, had a 36% decrease in 
specific binding of [^H]R5020 to cytoplasmic progestin 
receptors of the hypothalamus 12 hours post U-14,624. No 
effect was observed on the preoptic area, cerebral cortex or 
midbrain (MB) of the same animals. The percent of animals 
previously treated with EB or progesterone displaying 
lordosis (sexual behavior of female guinea pigs -a concave 
arching of the back that permits intromission by the male) 
was decreased by U-14,624. Based on the effects of clonidine 
and phenoxybenzamine on lordosis and cytoplasmic progestin 
receptors, they proposed that the modulation of target 
tissue responsiveness to steroids is an important mechanism 
by which neurotransmitters affect steroid-dependent 
processes.
Relying on the above premiss, Blaustein (1985) observed 
that the single dose of U-14,624 (150 mg/kg i.p.) which 
inhibited animals from showing lordosis, neither caused a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
decrease in MBH nuclear progestin receptors nor had any 
effect on the cytosol progestin receptors 5 hours after 
progesterone injection in ovariectomized guinea pigs. On the 
other hand, U-14,624 suppressed cytosol progestin receptors 
by 24.4% and increased nuclear progestin receptors by about 
92 fmol/mg DNA, when given after 500 ug of progesterone. To 
eliminate the possibility that the administered progesterone 
could mask the effect of U - 1 4 ,624, the experiment was 
repeated with a reduced dose of progesterone, 50 ug, and the 
entire hypothalamus was assayed instead of just the MBH. An 
18% decrease in cytosol progestin receptors and a 60.0 
fmol/mg DNA increase in nuclear progestin receptors was 
detected. It was concluded that inhibition of the 
noradrenaline (NA) system inhibits sexual behavior at a step 
beyond the retention of nuclear progestin receptors. 
Furthermore, Blaustein (1986) has shown U-14,624 (200 mg/kg 
i.p.) caused an 8 3% decrease in NE levels of the MBH 12 
hours post treatment in ovariectomized rats. No effect on 
the concentration of cytosol estrogen receptors in the MBH 
and anterior pituitary (AP) was observed at 3 or 8 hours 
post drug treatment. However, 15.2% and 21.8% decreases in 
the concentration of cytosol estrogen receptors were 
observed 12 hours post drug treatment in the MBH and AP, 
respectively. To eliminate the possibility that U-14,624 
could induce the release of adrenal estrogens.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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ovariectomized and adrenalectomized rats were treated with 
the same dose of U-14,624 and assayed for cytosol and 
nuclear estrogen receptors. A decrease in the concentration 
of cytosol estrogen receptors was observed similar to those 
seen in rats that were only ovariectomized. Also, U-14,624 
caused an increase in the concentration of nuclear estrogen 
receptors in the MBH and AP, demonstrating that the initial 
effect is not secondary to the release of adrenal steroids. 
U-14,624 did not compete with (^H) estradiol in v i t r o . 
suggesting that U-14,624 does not directly interact with 
estrogen receptors. It was concluded that the inhibition of 
DBH with the resultant decrease in ME increases the affinity 
of unoccupied estrogen receptors for cell nuclear 
components.
In an attempt to determine the mechanism by which 
catecholaminergic inhibitors decrease the accumulation of 
cytosol estrogen receptors in either the MBH or AP,
Blaustein et al <1986) not only confirmed the previously 
reported decrease in the concentration of cytosol estrogen 
receptors, but also demonstrated that other DBH inhibitors 
(diethyldiothiocarbamate and FLA-6 3) cause a decrease in the 
concentration of cytosol estrogen receptors. In no case was 
an increase in the concentration of nuclear progestin 
accumulation detected. This led them to conclude that the 
decrease in cytosol receptors caused by inhibitors of DBH in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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either the MBH or AP is not the result of increased 
accumulation of cell nuclear estrogen receptors.
Although the relationship between median eminence 
noradrenaline (NA) and circulating prolactin levels has not 
been established, data from the work of Morgan et al (1982) 
with ovariectomized and hypophysectomized rats suggests that 
there is a correlation. Inhibition of NA synthesis in the 
median eminence with U-14,624 (200 mg/kg i.p.) resulted in 
the suppression of serum prolactin levels. From this 
observation, it was suggested that the inhibition of DBH by 
U-14,624 may be more useful than alpha-methyltyrosine for 
determining the effects of various endocrine manipulations 
on NA turnover in the median eminence.
Gray and Rauh (1974) have shown that U-14,624 and other 
alpha-adrenergic blocking agents (tolazoline, phentolamine 
and phenoxybenzamine) antagonize the anticonvulsant action 
of methazolamide in the mouse, while consistent antagonistic 
action was shown by alpha-blockers. they did not observe any 
consistency in the activity of the beta-blockers 
(pronethalol, bunolol and dischlorisoproterenol). The action 
of phenoxybenzamine was reversed by X-dopa in a competitive 
m a n n e r , but X-dopa failed to reverse the action of U-14,624.
The stimulant effect of â-amphetamine has been suggested 
to be mediated through the indirect release of 
catecholamines (Hollister, 1974; Von Voigtlander and Moore,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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1973; Hanson, 1966). Because of this ability to interact 
with the catecholamine systems, effects that result from the 
administration of d-amphetamine should reflect the balance 
between dopaminergic and noradrenergic systems. Therefore, 
pretreatment with U - 1 4 ,624 subsequent to amphetamine 
administration should suppress those effects associated with 
noradrenergic systems, while amplifying those effects of the 
dopaminergic systems. Khalsa and Davis (1975) have shown 
that pretreatment with u-14,624 (25 - 75 mg/kg i.p.) 6 hours 
earlier reduced or prevented the hypermotility induced in 
rats by morphine sulfate (MS) and d-amphetamine sulfate 
(AS). It was later demonstrated that 6 hours was a more 
appropriate interval between the administration of U-14,624 
and AS in which to observe the inhibition of d-amphetamine- 
induced hyperactivity. In addition, Hollister et al (1974) 
observed that U-14,624 failed to block amphetamine- 
stimulated motor activity in rats pretreated with reserpine 
when amphetamine was given 1 hour post U-14,624.
Since all the studies on amphetamine-induced 
hyperactivity had been on acute bases, Khalsa and Davis 
(1977) decided to explore the effects of amphetamine- and 
morphine-induced motility during or after chronic 
administration of DBH inhibitors. Pretreatment with U - 1 4 ,624 
(25 mg/kg i.p. daily) and AMT (50 mg/kg i.p. twice daily) 
for 12 to 18 days antagonized hypermotility induced by MS
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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and AS. Whereas tolerance developed to the anti-MS action of 
AMT in 6 days, no anti-MS effect was observed with U-14,624 
for as long as 18 days. Animals pretreated with U-14,624 
developed tolerance to the anti-AS effect within 12 days, 
and those pretreated with AMT showed only slight tolerance 
to anti-AS action at day 18. Supersensitivity to the MS 
motor effects was observed at 28 and 52 hours after 
cessation of treatment.
Cheng et al (1975) have shown that d.-amphetamine-induced 
pecking in pigeons was not inhibited in those animals 
pretreated for 20 hours with U-14,624 (200 mg/kg po), even 
when brain NE level were reduced to 23% of control with no 
change in the DA level. On the other hand, AMT and 
dopaminergic receptor blocking agents (haloperidol, 
chlorpromazine and bulbocapnine) did reduce d-amphetamine- 
induced pecking. The brain DA level was observed to be 
reduced in the AMT pretreated pigeons. Because of the 
correlation between brain dopamine level and d-amphetamine- 
induced pecking response, it was concluded that d- 
amphetarnine-induced pecking response is mediated indirectly 
by the release of dopamine.
On the assumption that the noradrenergic system is 
involved in self-stimulation behavior, Davis et al (1975) 
have observed that rats pretreated with U-14,624 (600 mg/kg 
po) failed to show reacquisition of morphine and d-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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amphetamine self-administration. The same dose of U-14,624 
in pretreated rats blocked the development of drug 
conditioned reinforcement (self-administration behavior) by 
morphine and d-amphetamine. It has been demonstrated that 
oral doses of u-14,624 (300 and 600 mg/kg) and AMT (225 
mg/kg) blocked self-administration of ethanol in rats (Davis 
et al, 1978). While both doses of U-14,624 depleted brain NE 
and increased DA levels, only the 600 mg/kg dose caused an 
increase in central 5-HT levels. However, AMT caused a 
decrease in both NE and DA levels with no effect on 5-HT, 
suggesting that only the central noradrenergic system is 
responsible for the effects of AMT and U-14,624 on self­
administration of ethanol.
Other effects of U-14,624 attributed to its interaction 
with the adrenergic system include antagonism of alpha- 
methyIdopa-induced depression of SLMA and decreased 
formation of alpha-methylnorepinephrine (Dominic and Moore, 
1971). Based on this observation. Day et al (1973) showed 
that u-14,624 (200 mg/kg i.p.) abolished the 
antihypertensive action of alpha-methyldopa effectively. 
McIntosh and Barfield (1984) have observed that DBH 
inhibitors (U-14,624 and DDC) increased both mount and 
intromission latencies in rats and caused an increase in the 
length of post-ejaculatory refractory period. In addition, 
Kuhn et al (1978) have observed that rats pretreated with U-
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14.624 (100 mg/kg i.p.) had a reduction in para- 
hydroxynorephedrine (POHNOR) and norephedrine (NOR) 
formation with an increase in pana-hydroxyamphetamine (POHA) 
levels in their brains following amphetamine treatment. 
However, U-14,624 did not affect brain amphetamine content. 
The action of U-14,624 on brain amphetamine metabolism is 
based on the inhibition of DBH, the enzyme responsible for 
converting POHA to POHNOR and finally to NOR.
Using electrical self-stimulation as an index to study 
drug effects on the central nervous system (CNS), Cooper et 
al (1974) observed that U-14,624 (50 mg/kg i.p.) did not 
inhibit d-amphetamine-induced increase in electrical self­
stimulation in reserpinized rats, but AMT did antagonize 
the increase in electrical stimulation. It was suggested 
that self-stimulation is mediated by a central dopaminergic 
system. Furthermore, Stinus et al (1976) have shown that U-
14.624 (50 mg/kg i.p.) did not affect self-stimulation rates 
in reserpine-primed rats with electrodes implanted either in 
the area ventralis tegmenta or in the lateral hypothalamus. 
However, AMT in reserpine-pretreated rats inhibited self­
stimulation by 85% 3 hours after drug administration. Wise 
et al (1977) have observed that doses of DBH inhibitors 
(DDC, U-14,624 and FLA-6 3) which caused a dose-dependent 
decrease in NE, also caused a dose-dependent decrease in 
self-stimulation. In addition, Honma and Fukushima (1979)
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have shown that doses of ü-14,624 and FLA-6 3, which did not 
affect methamphetamine-induced slow head shaking behavior in 
rats, enhanced stereotyped gnawing behavior. The observed 
elevated levels of NE and suppressed levels of DA led them 
to suggest that the dopaminergic system is involved in self­
stimulation behavior.
Following pretreatment with U-14,624 (75 mg/kg i.p.), 
Breese et al (1975) observed that methyIphenidate-induced 
locomotion was not inhibited. Rather, U-14,624 produced a 
significant elevation in locomotor activity. AMT antagonized 
methylphenidate stimulated motor activity, suggesting that 
dopamine is important to the locomotor stimulant action of 
methylphenidate.
In their work dealing with X - d o p a ’s effect on 
electroencephalographs (EEC), Thut and Rech (1972) observed 
that pretreatment with U-14,624 (50 mg/kg i.p.) did not 
alter the desynchronization of EEC induced by isocarboxazide 
and X-dopa. It was then hypothesized that a centrally 
produced decarboxylate metabolite of X-dopa is responsible 
for the EEG desynchrony. This metabolite was proposed to be 
dopamine.
Based on the observation of Watanabe et al (1969) that 
DDC potentiates morphine analgesia and that the only 
commonality between morphine and DDC in enhancing analgetic 
action was due to their ability to lower plasma copper
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(Iwata et al, 1970), Bhargava and Way (1974) observed that 
u-14,624 (100 mg/kg i.p.) not only potentiated morphine 
analgesia, but also delayed the development of morphine 
tolerance. It was observed that the same dose of U-14,624 
inhibited naloxone precipitated withdrawal jumping in 
dependent animals. In contrast to the above observations, 
Davis and Khalsa (1973) have reported that pretreatment with 
U-14,624 (200 mg/kg i.p.) elevated the LD50 of i.p. morphine 
from 292 to 504 mg/kg, while tropolone, an inhibitor of 
catecholamine-O-methyltransferase, reduced the LD50 of 
morphine from 292 to 54 mg/kg, supporting the hypothesis 
that the function of brain catecholamines is critical to the 
lethality of morphine.
During an attempt to antagonize the lethal action of 
cocaine in rats with U-14,624, AMT and pimozide, Wilson and 
Holbrook (1978) found that these three drugs failed to alter 
either the convulsant action or the acute median lethal dose 
of cocaine. This suggests that the convulsant and/or lethal 
action of cocaine may not be mediated by catecholamines.
In their preliminary work, Khalsa and Davis (1974) 
observed that single doses of U-14,624 (50 or 70 mg/kg) 
given orally or i.p. which reduced food intake, also 
resulted in 30 to 35% loss in body weight of rats. This 
observation in addition to the possible involvement of 
central catecholaminergic systems in feeding behavior
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(Baile, 1974; Myer, 1975; Leibowitz, 1976), led Khalsa et al 
(1976) to study the effect of oral doses of U-14,624 on food 
consumption. It was observed that low doses of U-14,624 (50 
and 75 mg/kg) decreased food intake of rats on days 1 
through 3, while higher doses (450, 600 & 1000 mg/kg) not 
only caused a decrease in food intake, but also caused a 
reduction in body weight on the first two days following U-
14.624. Only one rat out of 6 died at the 600 and 1000 mg/kg 
doses. No significant difference in locomotor activity was 
observed in all sets of animal treated. The observed 
increase in DA levels, decrease in NE levels and no change 
in 5-HT levels caused by U-14,624 were consistent with 
established feeding behaviors, suggesting that noradrenergic 
systems promote feeding behavior. Furthermore, Hollister et 
al (1975) perceived that while U-14,624 (75 mg/kg i.p.) 
decreased NE levels and reduced food consumption, the same 
dose failed to block the anorectic response of AS.
Peripheral Inhibition of DBH:
Depletion of peripheral NE by inhibition of DBH has been 
difficult to demonstrate. Johnson et al (1970) were 
unsuccessful in establishing peripheral inhibition of U-
14.624, either by acute or repeated administrations.
Although U-14,624 was ineffective in myocardial NE 
depletion, it effectively inhibited the synthesis of NE from
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exogenous DA. After depleting myocardial NE with 
metaraminol, DA administration increased NE levels in the 
myocardium (Johnson et al, 1970). This increase in NE was 
completely blocked by a single dose of U-14,624 (50 mg/kg 
i.p.). However, rats treated with U-14,624 (200 mg/kg i.p.) 
after adrenalectomy to remove non-cardiac sources of NE, 
showed greater than 50% reduction in their myocardial NE.
The dose of U-14,624 which blocked the conversion of DA to 
NE in the metaraminol-treated animals had no effect on the 
myocardial NE levels of the adrenalectomized rats. Moreover, 
NE-H^ was used to show that U-14,624 had no effect on the 
release, uptake or retention of NE in the rat heart.
Other Effects of U-14.624 Presumably Unrelated to DBH
iDhibition;
Cohen et al (1975) have shown that U-14,624 (50 - 200 
mg/kg i.p.) prevented the neurotoxic action of 6-hydroxy- 
dopamine (6-OHDA) on the adrenergic nerves of the mouse 
atria and irises. At these doses U-14,624 did not block or 
interfere with the accumulation of catecholamines. It was 
proposed that these actions of U-14,624 were not related to 
DBH inhibition, since FLA-6 3, a known potent inhibitor of 
DBH, did not protect adrenergic neurons against 6-OHDA 
action. Furthermore, U-14,624 (150 mg/kg i.p.) antagonized
the diatobegenic action of alloxan. It was subsequently
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suggested that U-14,624 protection against the neurotoxic 
action of 6-OHDA and diabetogenic action of alloxan was by 
free radical scavenging. U-14,624 has been demonstrated to 
protect adrenergic nerves of mouse atria against the 
neurotoxicity of 5,7-dihydroxytryptamine or 5,7-DHT (Allis 
and Cohen, 1977). The ability of U-14,624 to protect against 
the degenerative actions of 6-OHDA, 5,7-DHT and alloxan 
indicates some common mechanism of action for these 
cytotoxic agents. In addition, Szelenyi and Brune (1988) 
have observed that U-14,624 (13.2 mg/kg intragastric) was 
effective in protecting against gastric mucosal damage. This 
action of U-14,624 was attributed to its free radical 
scavenging property also.
Small doses of U-14,624 (25 mg/kg/day) have been shown to 
impair the biotransformation of pentobarbital and antipyrine 
(Smith et al, 1980). Decreased pentobarbital 
biotransformation was attributed to reduced drug clearance 
with increased sleeping time. This effect could be possibly 
due to the inhibition of barbiturate inactivation by the 
microsomal enzymes in vivo. Decreased antipyrine 
biotransformation was associated with a prolonged plasma 
half-life probably via reduced hydroxylase activity. 
Furthermore, doses of U-14,624 (50 - 200 mg/kg i.p.) were 
shown to suppress the activities of three other oxidative 
enzymes (aminopyrine N-demethylase, aniline hydroxylase and
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p-nitroanisole 0-demethylase). Suppression of these enzymes 
was positively and highly correlated with the reduced levels 
of hepatic microsomal cytochrome P-450, implying that U-
14.624 exerts its metabolism effect on cytochrome P-450. 
Smith et al (1982) have shown that accumulation of u-
14.624 in tissues is correlated with their rate of blood 
flow. Those tissues with high blood flow (liver, kidney, 
lung, brain and heart) achieved greater concentration of u-
14.624 than did those with low blood flow at rest (skeletal 
muscle and fat). They reported that U-14,624 is freely 
soluble in acetone, chloroform, dimethyl sulfoxide (DMSO) 
and N ,N-dimethylfomamide. Of these solvents only DMSO 
appeared to be safe solvent for U-14,624 administration in 
vivo. In addition Smith (unpublished work) observed that the 
plasma half-life of U-14,624 is 1.8 hours at 50 mg/kg i.v. 
and 9.4 hours at 200 mg/kg i.p.
Metalloproteins and Drug Metabolism;
Certain enzymes require essential cofactors for activity. 
These cofactors can be either inorganic elements (such as 
iron, manganese, zinc and copper ions) or complex organic 
molecules called coenzymes. In some cases both the coenzyme 
and one or more metal ions are required by the enzyme. These 
cofators can be transiently or permanently bound. Enzymes 
that require a metal ion for activity are called
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metalloenzymes or metalloproteins. The inorganic elements 
appear to function in three different ways (Tuckerman and 
Turco, 1983; Adam, 1985; Lowe et al, 1985; Greenwood, 1985; 
Thomson, 1985; Hofmann, 1985):
a) By having inherent activity in catalyzing a chemical 
reaction to enhance the enzyme action.
b) By forming a complex with both substrate and enzyme 
active site to activate the enzyme.
c) By functioning as a potent electron withdrawing agent 
in a catalytic cycle.
Therefore, any chemical compound that has the ability to 
partially or completely antagonize these elements, either by 
chelation or displacement, would inhibit the action(s) of 
the enzymes. The possibility of selectively inhibiting the 
action of an enzyme by this mechanism has resulted in a 
considerable interest in the search for inhibitors of 
metalloproteins.
Taurgo (1976) proposed that thioureylene antithyroid 
drugs act by inhibiting the microsomal enzyme,thyroid 
peroxidase, thereby preventing the oxidation of iodide or 
iodotyrosyl groups. Subsequently, Davidson et al (1978) and 
Engler et al (1982) reported that antithyroid drugs bind to 
and inactivate the peroxidase enzyme only when the heme of 
the enzyme is in the oxidized state.
Angiotensin converting enzymes (ACEs) from rabbit and dog
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lungs, and horse plasma have been shown to contain about one 
gram-atom of zinc (Das and Soffer, 1975; Conroy et al, 1978; 
Fernley, 1977). ACE is involved in the synthesis of 
angiotensin II from angiotensin I. Angiotensin II is known 
to cause vasoconstriction of blood vessels and stimulate the 
release of aldosterone with the net result being a rise in 
the blood pressure. Captopril, the prototypal competitive 
inhibitor of ACE, has been suggested to exert its 
antihypertensive action by binding strongly to the zinc ion 
at the active site of the enzyme (Cushman et al, 1977; 
Ondetti et al, 1977).
Besides functioning as cofactors, inorganic elements are 
required in animal nutrition for proper growth and 
biological function. Some of these inorganic elements may be 
required in relatively large amount per day (bulk elements) 
or only in very small amounts (trace elements). The bulk 
elements include calcium (Ca), magnesium (Mg), sodium (Na), 
potassium (K), phosphorus (P), sulfur (S) and chloride (Cl). 
Calcium is a structural component of the bone in the form of 
hydroxyapatite, Ca^g(P0^)g(0H )2 and also serves as an 
important regulatory agent in the cytosol (Avioli, 1988). 
Phosphorus in its phosphate form is an essential component 
of the intracellular energy-transferring system, involving 
ATP (Avio.li, 1988). As a component of the skeletal muscle, 
skin, nervous tissue and other organs, it is essential for
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the metabolism of carbohydrate, fat and protein and 
functions as a cofactor for a multitude of enzyme systems 
(Avioli, 1988; Tuckerman and Turco, 1983).
The trace elements can further be divided into essential 
and nonessential groups. It is the essential trace elements 
that function as enzyme cofactors or prosthetic group. Below 
is a synopsis of trace elements and their biological 
functions in a tabular form (Tuckerman and Turco, 1983; 
Stanburg, 1988; Solomons, 1988; Levander, 1988; Fairbanks 
and Beutler, 1988):
BIOLOGICAL FUNCTIONTRACE ELEMENTS 
Iron (Fe)
Iodine (I)
Copper (Cu)
Manganese (Mn)
Zinc (Zn)
Selenium (Se)
Prosthetic group of heme enzymes and 
a component of hemoglobin and 
myoglobin.
An integral part of the thyroid 
hormones, (thyroxine and 
triiodothyronine).
A constituent of many enzymes, 
required for the proper utilization 
of iron, in energy metabolism and 
development of bone, connective 
tissue and CNS.
A cofactor for many enzymes involved 
in the metabolism of protein and 
energy, and the formation of 
mucopolysaccharides.
Is an essential component of over 100 
enzymes, is required for mobilization 
of vitamin A from the liver, and is 
involved in the synthesis of protein 
and nucleic acids.
Cofactor of glutathione peroxidase.
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The influence of the endocrine system on drug metabolism 
has been extensively studied. This influence could be 
exerted by interfering with either the adrenocortical and/or 
thyroid hormone functions.
Furner and Stitzed (1968) have demonstrated that 
adrenalectomy reduced the rate of ethylmorphine, aniline and 
hexobarbital metabolism in rats, an effect attributed to the 
decrease in liver microsomal enzymes, in addition, Minegishi 
et al (1968) have shown that adrenalectomy decreased the 
activities of demethylating enzyme in rats. Brodie et al 
(1961) have reported that endocrine-stimulated rats 
exhibited marked alteration in lipid metabolism which can be 
initiated by drugs acting on the pituitary-adrenal axis. 
Stimulation of the pituitary-adrenal axis affects the 
corticosteroid-induced synthesis of many liver enzymes 
responsible for carbohydrate and amino acid metabolism. 
Bousquet et al (1965) have demonstrated that the pituitary- 
adrenal axis could serve a regulatory function with respect 
to the duration of drug responses that are mediated by 
alteration of drug metabolism.
Hayes and Murad (1985) have reported that the thyroid 
hormones regulate growth, development, metabolism and basal 
metabolic rate (BMR). Therefore any factor(s ) that could 
affect the euthyroid state of a mammal could also affect 
processes dependent on thyroid hormone function.
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Oxygen consumption is a sensitive and reliable procedure 
to determine the BMR (Baker, 1956). Baker and Klitgaard 
(1952) observed that the time course of tissue metabolic 
changes following single injection of thyroxine in 
thyroidectomized rats was highly correlated with oxygen 
consumption in the entire animal. Of all the tissues 
studied, only the liver, kidney, heart, gastric mucosa and 
skeletal muscle were responsive to thyroxine. In addition, 
Whaley et al (1959) have observed that the injection of 
thyroid hormones (thyroxine and triiodothyronine) in the 
intact rat caused a significant increase in the BMR within 
12 hours. The tissue oxygen consumption of the liver, 
kidney, heart, gastric mucosa, skeletal muscle and diaphragm 
were significantly increased above the control value.
Drabkin (1950a) has associated the oxidative capacity of a
tissue with its cytochrome c (cyt. c) content, it was
observed that the decreases and increases in cyt. c were 
correlated with hypo- and hyperthyroidism. Tissues high in 
cyt. c (liver, kidney, cortex and heart) seem to react more 
quickly than those with lesser amounts of the enzyme. This
led him to conclude that there may be a functional
relationship between the thyroid gland and cyt. c. 
Furthermore, Freedland (1965) have shown that the activities 
of several liver enzymes were increased by the 
administration of thyroxine.
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Malbon et al (1984) have shown that there is an 
interaction between the hsia-adrenergic receptors and 
thyroid hormone. Hypothyroid rats failed to synthesize 
cyclic AMP in response to beta-adrenergic agonists. Handlers 
et al (1983) have reported that the administration of 
triiodothyronine to euthyroid humans resulted in increases 
in gluconeogenesis, glycogenolysis. lipid mobilization, 
ketogenesis and proteolysis.
In his work on cyt. c metabolism and liver regeneration, 
Drabkin (1950b) observed that adrenalectomized rats had 
reduced concentration of cyt. c in all tissues examined 
(liver, heart, kidney, cortex and skeletal muscle). Drabkin 
(1950b) had previously observed that hypothyroidism caused a 
decrease in the cyt. c of these tissues. He then 
hypothesized that there is probably an interdependency 
between the adrenal hormone and the thyroid hormone. In 
addition, Preedlander et al (1968) have observed that the 
usual increase in enzyme activities associated with 
thyroxine administration was drastically decreased or 
eliminated in the adrenalectomized rats. This strongly 
suggests a thyroxine-adrenal interaction in the intact 
animal. Although hypophysectomy had a similar effect, it was 
attributed to the lack of adrenal function. Prom these 
observations, they concluded that the pituitary and/or 
adrenals are permissive for thyroxine's effect on enzyme
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activity.
Drug metabolism (xenobiotransformation) involves the 
formation of more polar, water-soluble derivatives, which 
usually results in the reduction of pharmacological activity 
with more rapid clearance. These derivatives usually contain 
more hydrophilic functional groups or are conjugated with 
relatively hydrophilic moieties. The excretion of 
biotransformed parent drug can occur through the kidney by 
tubular secretion, glomerular filtration or both (Smith and 
williams, 1966). Polar metabolites greater than 500 daltons 
are predominantly eliminated through the bile.
Most drug metabolism occurs in the liver, which 
contains the enzymes responsible for drug metabolism in the 
soluble, mitochondrial and microsomal fractions. Drug 
metabolism can involve phase I reactions (oxidation, 
reduction and hydrolysis) and phase II reactions or 
conjugations. A drug can be subjected to several competing 
and simultaneous pathways. The relative rates of the various 
interactions determine the extent of metabolite generation. 
However, the most typical sequence involves a phase I 
reaction preparatory for a phase II process. Alcohols, 
phenols, aromatic and some aliphatic carboxylic acids, amino 
acids, amines, and certain thio groups are prerequisite for 
the conjugation process.The major conjugation pathways that 
occur in mammalian species are : glucuronic acid conjugation
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(glucuronidation), sulfate conjugation (sulfation), glycine 
conjugation, glutamine conjugation, acétylation, mercapturic 
acid synthesis from glutathione, and méthylation (Mandel, 
1981).
U-14,624 has ben shown to chelate some heavy metals with 
varying degree of sensitivity (Uno, 1960). Also the 
classification of U-14,624 as a DBH inhibitor, is based on 
its ability to chelate the copper ions of the enzyme. 
However, it is unknown if U-14,624 is a general or specific 
chelator of heavy metals. This work was undertaken to 
investigate the selectivity and specificity of U-14,624. 
Three metalloproteins (pseudocholinesterase, angiotensin 
converting enzyme and thyroid peroxidase) that require metal 
ions for their optimal activity were used to assess the 
selectivity and specificity of U-14,624. Previous in vivo 
interaction between these metalloproteins and U-14,624 had 
not been investigated or reported.
U-14,624 has been shown: A) to accumulate in tissues 
(Smith et al, 19 82) and B ) to subsequently disappear from 
plasma and tissues (liver, kidney and brain; Smith, J. R. 
unpublished), suggesting that this lipophilic compound is 
being metabolized. The second phase of this work sought to 
determine the major metabolic pathways (sulfate and 
glucuronides) of U-14,624.
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MATERIALS AND METHODS
ANIMALS AND HOUSING
Sprague-Dawley rats (Bantin & Kingman Co. Fremount, CA) 
weighing at least 250mg were used. No more than four rats 
were housed together in a wire-mesh cages over wood-chip 
bedding. Purina lab chow and water were available ad l i b . 
during 12 hour light-dark cycles. Rats used for the 
glucuronidation experiment were housed individually during 
urine collection in a metabolism cage (Hoeltge Inc. 
Cincinnati, Ohio). The rats where taken off food during 
collection of urine, to avoid contaminating the urine with 
food.
New Zealand rabbits (R & R Rabbitory, Standwood, WA) 
weighing at least 1.36 kilograms were used in chronic 
studies. Only one rabbit was housed per cage in a wire-mesh 
cages over wood-chip bedding.
All animals were allowed a minimum of 10 days 
acclimatization before starting the experiments.
REAGENTS AND DRUGS
Drugs and reagents were obtained from the indicated 
sources. Dextran (average MW 78,500), Choiinesterase kit, 
Carbazole, Angiotensin Converting Enzyme (ACE) kit, 1-
30
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Phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624) and D- 
glucuronic acid (Sigma Chemical Co. St Louis, Mo). 
Trichloroacetic Acid (TCA), Sodium sulfate (NaSO^), Ethanol, 
Sodium tetraborate. Sodium bisulfite (NaHSOg), Mercury 
chloride (HgClg), Sodium bicarbonate (NaHCOj) and Dimethyl 
sulfoxide, DMSO (Baker chemical Co. Phillisburg, NJ). Barium 
chloride (Mallinckrodt chemical works, St Louis, Mo).
TUCEDIA Assay (Microgenics, Concord, CA). Sulfuric acid 
(EM Science, Cherry Hill, N J ) . Acetic acid (VWR, San 
Francisco, CA). Alconox detergent (Alconox Inc. New York,
NY) and Sodium pentobarbital (Robinson Lab Inc., San 
Francisco, CA).
U-14,624 was dissolved in DMSO to achieve concentrations 
of 50 to 200 mg/ml.
EXPERIMENTAL PROTOCOL
Pseudocholinesterase:
U-14,624 was administered intraperitoneally (i.p.) at 
concentrations of 50 to 200 mg/kg. All drug administrations 
were in a constant volume of 1 ml/kg to ensure that the 
concentration of DMSO was constant. Blood was collected from 
pentobarbital anesthetized animals by means of abdominal 
aortic puncture. Blood samples (6-10 ml) were drawn and 
emptied into a 15 ml glass centrifuge tubes. The samples
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were prepared for analyses as described in appendix A.
A Sigma diagnostic kit (No. 420) was used for analyses.
The assay is based on the use of an indicator, m-nitophenol, 
to measure the acetic acid produced by the hydrolysis of ' 
acetylcholine by pseudocholinesterase (Rappaport et al, 
1959). The acetic acid produced lowers the pH of the assay 
mixture causing a loss of color. The change in color is 
proportional to the amount of pseudocholinesterase present. 
Analyses were performed on a Bausch and Lomb Spectronic 600 
in the double beam mode at 420nm.
Angiotensin Converting Enzyme:
Acute studies were done in rats. U-14,624 was 
administered i.p. at concentrations of 50 to 200 mg/kg.
Blood was collected by aortic puncture. Blood samples (6-10 
ml) were drawn and emptied into 15 ml glass centrifuge 
tubes.
Chronic studies were done in rabbits, u-14,624 was given 
i.p. at 50mg/kg/day for 8 days. The drug was administered in 
volume of 0.25 ml/kg. Sampling was done every other day. Two 
to three ml of blood was collected from the marginal ear 
vein.
All blood samples were prepared for analyses as described 
in appendix A.
ACE activity was determined by the Holmquist et al (1979) 
method, based on the cleavage of N - (3-(2-furyl)aeryloi)-L-
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phenylalanylglycylglycine (PAPGG) to furylacroloylphenyl- 
alanine (PAP) and glycylglycine (GG) by ACE (Sigma 
diagnostics kit, procedure No. 305-UV). The cleavage of 
PAPGG to PAP and GG results in decreased absorbance. The ACE 
activity is determined by comparing the sample reaction rate 
to that obtained with the provided ACE calibrator. Analyses 
were performed on a Bausch and Lomb Spectronic 600 with a 
constant temperature cuvette chamber, in a double beam­
mode.
Thyroxine (T^
u-14,624 was administered to two rabbits at the 
concentrations of lOO mg/kg i.p. (acute dose). After a wash­
out period of 5 days, the same rabbits were used for chronic 
study (50 mg/kg/day i.p.). Drug was administered in a volume 
of 0.25 ml/kg. Drug dosing was done for 7 days and blood 
sampling was performed daily for 14 days. Two to three ml of 
blood was collected from the marginal ear vein. Samples were 
prepared for analyses as described in appendix A.
T^ levels were determined by the Microgenics CEDIA™
T^ Assay adjusted for macroanalyses based on recombinant DNA 
technology. In the procedure beta-galactosidase enzyme is 
split into two fragments, an enzyme-donor (ED) and an 
enzyme-acceptor (EA), which can spontaneously recombine to 
form an active enzyme. Thyroxine is covalently attached to 
the ED in such a way as not to interfere with the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
34
spontaneous reassociation of ED and EA. Binding of 
thyroxine-specific antibody to the enzyme associated 
thyroxine will inhibit the reassociation of ED and EA, 
thereby regulating the amount of the enzyme, beta- 
galactosidase, formed. Serum thyroxine competes for the 
limited number of anti-thyroxine binding site to regulate 
the assembly of ED and EA. The concentration of thyroxine 
contributed by serum in the assay mixture is proportional to 
the amount of beta-galactosidase formed. The reaction is 
monitored by the ability of beta-galactosidase to hydrolyze
0-nitrophenyl-B-D-galactopyranoside (ONPG) to a-nitrophenol 
at 420nm. The concentration of T^ in the sample is 
determined from a standard curve. Analyses were performed on 
a Bausch and Lomb Spectronic 600, with a constant 
temperature cuvette chamber, in the double beam-mode. 
Sulfation of U-14.624:
U-14,624 was administered i.p. at concentrations of 50 to 
200 mg/kg. Blood was collected by means of abdominal 
aortic puncture. Blood samples (6-10 ml) were withdrawn and 
emptied into 15 ml glass centrifuge tubes. The sample were 
prepared for analyses as described in the appendix A.
Concentration of serum inorganic sulfate was determined 
by the turbidimetric method of Berglund and Sorbo (1960) as 
modified by Krijgsheld et al (1979). Analyses were done on 
Bausch and Lomb Spectronic 600 in the double beam-mode.
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Glucuc<?ni<aa t ion af... U.-1.4 .624 ;
Urine from adult male rats were collected for 24 hours 
before and after treatment with DMSO (1 ml/kg) or U-14,624 
(200 mg/kg i.p.)* Urine collection was done in a metabolism 
cage. Large rubber tubing was connected from metabolic cages 
to 50-ml erlenmeyer flasks to minimize evaporative urine 
loss. The urine was filtered with Whatman** 52 filter paper 
and diluted 50 fold with distilled water before analyses as 
described in the appendix A.
The Yuki and Fishman (1963) Carbazole Method for 
differential analysis of glucuronidation, glucosiduronate 
and hyaluronate was used to determine the total amount of 
conjugated glucuronides per 24 hours in rat urine. Analysis 
was performed on a Bausch and Lomb spectronic 600 in the 
double beam mode.
Statistical Methods;
The student t-test for independent and dependent samples 
was used to test for statistical significance (p<0.05) 
between U-14,624, DMSO treatments and non-solvent controls.
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RESULTS
Pseudocholinesterase activity:
Single doses of U-14,624 (100 mg/kg i.p.) decreased serum 
pseudocholinesterase enzyme activity after 6 to 18 hours 
(Fig 1). The most pronounced decrease in enzyme activity was 
observed at 12 hours. There was no significant difference in 
enzyme activity between the 24 and 30 hours treatments and 
the control (i = 1.525; df - 13; p<0.05). The solvent, DMSO 
(1 ml/kg i.p.), had no effect on the serum pseudo 
cholinesterase activity. Using the time of the most 
pronounced decrease in enzyme activity, 12 hours, a dose- 
dependent decrease in enzyme activity was observed, which 
levelled-off at doses exceeding 75 mg/kg i.p. (Fig 2). 
Angiotensin converting enzyme fACE) activity:
Acute doses of U-14,624 (50 to 200 mg/kg i.p.) and DMSO 
(1 mg/kg i.p.) in rats did not result in any significant 
difference in ACE activity. (p>0.05 Fig 3).
Chronic dosing of U-14,624 (50 mg/kg/day i.p.) in rabbits 
had a pronounced effect on ACE activity (Fig 4). There was a 
51% to 65% decrease in ACE activity from day 18 to 24 of the 
experiment. The solvent, DMSO, had minimal effect on ACE 
activity (181 U/L on days 11 to 15) when compared to the
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absolute control.
The experiment was prematurely terminated due to the 
death of two rabbits on day 25. During the control and DSMO 
treatment periods, the weights of the rabbits were either 
static or increased slightly. However, when U-14,624 
treatment was initiated, the rabbits became emaciated as 
evidenced by the 15% to 18% drop in body weight (Table 1). 
ThyrQxing.iT̂ )
Acute doses of U-14,624 (100 mg/kg i.p.) in 2 rabbits, 
caused a maximal of suppression of T^ levels on day 4 (36% 
and 48%, respectively). The suppressed T^ levels were 
essentially recovered on day 7 (Fig 5).
Chronic dosing of U-14,624 (50 mg/kg/day i.p.) in 2 
rabbits resulted in 68% and 62% decrease in T^ levels on day 
7 (Fig 6). The onset of T^ suppression was evidenced as 
early as day 3 (41% and 50%, respectively). Drug adminis­
tration was terminated on day 7 due to drug toxicity, as 
indicated by the 16% and 31% drop in body weights (Table 2). 
Sulfation:
Single doses of U-14,624 (100 mg/kg i.p.) caused a 
significant decrease (p<0.05) in serum sulfate levels after 
6 to 18 hours (Fig 7). The serum sulfate levels at 6, 12,
18, 24 and 30 hours were 58%, 45%, 81%, 90% and 92% of 
control (96 ug/ml). The maximal depletion of sulfate was 
observed at 12 hours. There was no significant difference
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between the control sulfate level and the 24 and 30 hours 
treatments. The solvent, DMSO (1 ml/kg i.p.), had no 
significant effect (p>0.05) on the serum sulfate level.
A dose dependent decrease in serum sulfate levels which 
leveled-off at doses exceeding 75 mg/kg i.p. was observed at 
12 hours post drug administration (Fig 8).
Glucuronidation:
No significant difference (i = 0.4398, df = 5, p > 0 .05) in 
the amount of conjugated glucuronides per 24 hours was 
observed between the absolute control and the solvent 
treated (1 ml/kg i.p.) rat urines (Table 3). However, a 
significant increase (i =» 3.25 37; df = 5; p<0.05) in the 
amount of conjugated glucuronides per 24 hours was observed 
between the absolute control and U-14,624 treated (200 mg/kg 
i.p.) rat urines. When the solvent treated and U-14,624 
treated rat urines were compared, there was no significant 
difference (t = 1.8478; df = 5; p > 0 .05).
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I- Comparison of pseudocholinesterase activity across 
time for drug (u-14,624 100 mg/kg i.p.) and nondrug 
treatments. Treatments are as indicated in the legend with 
the data points depicting the mean ± S.E.M. at indicated 
time. The number of rats used is given above the S.E.M. 
bars. And asterisk (*) indicates p<0.05.
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Pig. 2. Effects of increasing U-14,624 doses on 
pseudocholinesterase activity. The treatments are as 
indicated in the legend. Number of rats used is given above 
the S.E.M. bars and an asterisk (*) indicates p<0.05.
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Acute E ffec ts  o f U—1 4 .624  
on ACE, a Zinc Metal loprotein
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Fig. 3. Effects of acute doses of ü-14,624 on ACE activity, 
Treatment are as indicated in the legend. Number of rats 
used is given above the S.E.M. bars and asterisk (*) 
indicate p<0.05.
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Pig. 4, Effect of treatments on ACE activity across days. 
Treatment is as indicated in the legend. Number of rabbits 
used is given above the S.E.M. bars.
After day 3 only three rabbits were left due to loss of one 
rabbit.
Only 2 rabbits data were used on day 7 due to blood 
hemolysis which caused absorbance reading to be off scale.
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Acute E ffects of U - 14 ,624  on Thyroid 
Peroxidase, Evidenced by Thyroxine level
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Fig. 5. Thyroxine levels across days after acute treatment 
with U-14,624 (100 mg/kg i.p.) expressed as percent control 
Plus (+) indicates that blood hemolysis was present in the 
serum which could explain thyroxine levels greater than the 
control.
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Chronic E ffects  of U -1 4 ,6 2 4  on thyroid 
Peroxidase, Evidenced by Thyroxine level
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Pig. 6. Thyroxine levels across days during and after drug 
(50 mg/kg i.p.) treatment in rabbits expressed as percent 
control. Plus (+) indicates that blood hemolysis was present 
in the serum which could explain thyroxine levels greater 
than control.
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M ODIFICATION OF PLASMA SULFATE LEVELS
ACROSS TIME
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Pig. 7. Comparison of serum sulfate across time for drug and 
nondrug treatments. Treatments are as indicated in the 
legend with the data points depicting the mean ± S.E.M. at 
the indicated times. The number of rats used is given above 
the S.E.M. bars and asterisk (*) indicates p<0.05.
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Fig. 8. The effect of increasing U-14,624 doses on serum 
sulfate depletion. The treatments are as indicated in the 
legend. Number of rats used is given above the S.E.M. bars 
and an asterisk (*) indicates p <0.05.
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TABLE 1.
Kilogram body weight of rabbits during chronic treatment
with U-14,624 (50 mg/kg i.p.)
Day 1
Rabbits
2 3
17 2. 38 2.21 2. 21
18 2. 32 2.13 2.15
19 2.32 2.15 2.10
20 2.23 2.15 1. 98
21 2.21 2.12 1.93
22 2.14 2.10 1.87
23 2.10 2.04 1.87
24 2.01 2.04 1. 81
25 died 1.90 died
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TABLE 2
Kilogram body weight of rabbits during drug 
(U-14,624 50 mg/kg i.p.) treatment across days
Day
Rabbits
1 2
0 1.36 1.76
1 1. 30 1.66
2 1. 30 1.60
3 1.25 1.62
4 1.21 1.60
5 1.14 1.50
6 1.12 1.40
7 1.02 1.17
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TABLE 3
comparison of the amount of conjugated glucuronides 
(mg/24 hours) in the rat urine across treatments.
Rat Control
Treatments
DMSO® U-14,624^
1 17.37 47. 44 40.18
2 30.19 17.05 39.85
3 20.50 25.90 24. 86
4 24.05 15. 86 31.61
5 28.60 31. 63 51.42
6 42. 76 41. 86 46.10
Not significantly different from the control 
(i = 0.4398; df - 5; p>0.05).
Significantly different from control 
(i = 3.254; df = 5; p<0.05).
Not significantly different from DMSO 
(i - 1.8478; df = 5; p>0.05).
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chapter 4 
DISCUSSION
Acute administration of U-14,624 produced a decrease in 
serum pseudocholinesterase activity (Fig. 1). Although, the 
mechanism of U-14,624 action on this enzyme is unknown, it 
has been established that the pseudocholinesterase enzyme 
requires calcium and magnesium ions as activators 
(Augustinsson,1960). U-14,624 is a known chelator of di- and 
tri- valent ions at very low concentration (Uno, 1960) and 
could be inhibiting the enzyme activity by this mechanism. 
Augustinsson (1960) and Golz (1966) have reported 
organophosphate esters, carbamate derivatives and quaternary 
ammonium salts to be inhibitors of pseudocholinesterase 
enzyme by binding to the active site with the degree of 
their inhibition dependent on the rate of inhibition 
reversal. Carbamate derivatives are known to have 
intermediate rates, while the organophosphate esters are 
known to have either extremely slow or insignificant rates 
of inhibition reversal. The observed leveling off in enzyme 
activity with U-14,624 at doses exceeding 75 mg/kg i.p. 
could be due to the slow reversal of U-14,624 inhibitory 
action (Fig 2).
While acute doses of U-14,624 in rats did not have any 
significant effect on ACE activity (Fig. 3), chronic dosing
50
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of U-14,624 in rabbits had a pronounced effect on ACE 
activity (Fig. 4). A 51% to 65% decrease in ACE activity was 
observed. Most ACE inhibitors that are employed 
therapeutically exhibit their useful responses during long­
term treatments (Douglas, 1985), which could rationalize the 
lack of U-14,624 effect on ACE activity with acute 
treatment. Das and Soffer (1975), Conroy et al (1975), and 
Fernley (1977) have shown that ACE's from rabbit and dog 
lungs and horse plasma contain about one gram-atom of zinc. 
In addition, captopril, a potent competitive inhibitor of 
ACE, exerts its inhibition by an interactive binding of its 
sulfhydryl group with the zinc ion at the active site of ACE 
(Cushman et al, 1977; Ondetti et al, 1977). Therefore, U-
14,624 could be exhibiting its effect by either chelating 
the zinc ion in the plasma that is needed for ACE activity 
or the sulfur containing moiety of U-14,624 could be 
interacting with the zinc ion of ACE at the active site of 
the enzyme.
Antithyroid drugs exert their effects by inhibiting the 
iodide organification process of thyrohormogenesis. They act 
by serving as alternative substrates and consequently are 
iodinated and metabolized, thus directing oxidized iodide 
away from thyroglobulin resulting in a depressed thyroid 
hormone synthesis. Taurog (1976) first proposed that 
thiourelylene antithyroid drugs act on the peroxidase enzyme
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by interfering with both the incorporation of iodine into 
tyrosyl residues and the coupling of iodotyrosyl residues to 
form iodothyronines. In addition to confirming Taurog's 
work, Davidson et al (1978) observed that the function of 
thyroid peroxidase which is inhibited by drugs is 
irreversible and is hydrogen peroxide dependent. Therefore, 
U-14,624 could be exerting its effect on thyroid peroxidase 
by free radical scavenging. Inactivation of thyroid 
peroxidase by methyImercaptoimidazole and propylthiouracil 
involves an interaction between the drug and the oxidized 
heme group produced by the interaction between thyroid 
peroxidase and hydrogen peroxide (Engler et al, 1982). 
Johnson et al (1969) have shown that disulfiram and u-14,624 
do chelate copper ions and copper is essential for proper 
utilization of iron. U-14,624 could be interfering 
indirectly with heme biosynthesis which may result in 
reduced levels of the heme-containing peroxidase enzyme.
The observed decrease in thyroxine level post U-14,624 
implies that U-14,624 either directly or indirectly does 
interact with the thyroid peroxidase enzyme. Moreover, all 
drugs employed in the treatment of hyperthyroidism have a 
thiourea group, which interacts with thyroid peroxidase 
enzyme resulting in their antithyroid action (Cooper, 1984).
The latent period to the onset of suppressed thyroxine 
levels was very short, considering that circulating
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thyroxine has a half-life of 6 to 7 days, except in 
hyperthyroidism where it is shortened to 3 or 4 days. 
Inhibition of thyroid synthesis usually takes 1 to 2 weeks 
for suppressed thyroxine levels to be observed. A plausible 
explanation for the relatively sudden onset of suppressed 
thyroxine is that U-14,624 could be interfering with release 
of thyroid hormone from thyroglobulin by acting on the 
responsible proteolytic enzyme. Schimner and Georger (1989) 
have reported that iodide and lithium carbonate inhibit the 
release of thyroid hormones from thyroglobulin. Whereas 
lithium carbonate is proposed to act by inhibiting the 
thyroid adenylcyclase, the mechanism of iodide action is not 
known.
The inhibitory effect of u-14,624 on pseudo- 
cholinesterase, ACE and thyroid peroxidase enzymes have been 
proposed to be due to the ability of u-14,624 to chelate 
heavy metal ions. However, some of these effects could 
result from the toxicity of U-14,624 as evidenced by the 
pronounced decrease in weight of the rabbits during chronic 
dosing (Tables 1 & 2). Khalsa and Davis (1974), Hollister et 
al (1975) and Khalsa et al (9176) have reported that U-
14,624 caused a reduction in food intake in animals with 30% 
to 34% weight loss. Zinc-deficiency has been shown to cause 
growth retardation in rats (Bicking and Morrism, 1970). 
Furthermore, an optimal copper level has been shown to be
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required for maximal enzyme activity, and either copper 
excess or deficiency would diminish enzyme activity (Murphy, 
1973).
With its ability to chelate di- and tri-valent ions, U-
14,624 might be interfering with various metalloproteins, 
which could result in these proteins not functioning 
properly. In addition, most studies that employ U-14,624 
gave the drug as a suspension, with the possibility of the 
absorption being erratic. Kohn et al (1982) in attempt to 
repeat the previous work of Kalara et al (1972) reported 
that U-14,624 dissolved in DMSO caused more suppression of 
gonadotropin levels in rats than did a suspension of u- 
14,624.
Previous unpublished work in this laboratory has shown 
the elimination half-life of U-14,624 to be 1.8 hours when
administered at 50 mg/kg i.v. and 9.4 hours when
administered at 200 mg/kg i.p. Declining plasma and tissues 
(liver, kidney and brain) levels of U-14,624 were observed, 
suggesting that this highly lipophilic compound is being 
metabolized to more polar substances. According to Brodie 
(1964), metabolism is a necessary prerequisite for the 
mobilization of very lipophilic drugs. Drug metabolism can 
involve phase I reactions (oxidation, reduction and
hydrolysis) and phase II reactions or conjugations. A drug
can be subject to several competing and concurrent pathways.
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However, the most usual sequence involves a phase I reaction 
preparatory for a phase II process. The latter process 
requiring endogenous cosubstrate such as activated sulfate 
(PAPS, 3'-phosphoadnosine 5'-phosphosulfate), glucuronic 
acid, amino acids (glutamine, glycine, ornithine) and 
reduced glutathione (mercapturic acid conjugation). These 
endogenous substrate are limited in quantity and often 
restrict the rate of drug conjugation (Levy and Yamada,1971; 
Galinsky et al, 1979; Slattery and Levy, 1979).
Morris and Levy (1983) and Lif% and Levy (1981) have shown 
that acetaminophen administration resulted n the decrease of 
endogenous serum inorganic sulfate in both humans and rats. 
They observed that serum sulfate levelled off at higher 
doses of acetaminophen (150 & 300 mg/kg i.v.). Galinsky and 
Levy (1981) have observed that acetaminophen accumulation in 
the plasma was associated with a definite change in the 
formation of acetaminophen conjugates. Sulfation, the 
initial predominant route for acetaminophen metabolism, 
decreased with time and relatively more of the drug was 
metabolized by glucuronidation. Moreover, the extent of 
sulfation was positively correlated with decrease in serum 
sulfate, suggesting that the ultimate source of active 
sulfate was serum derived.
The decrease in serum inorganic sulfate levels (Fig.7) 
produced by U-14,624 (100 mg/kg i.p.)indicates that
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endogenous inorganic sulfate is being utilized as 
cosubstrate for U-14,624 conjugation. The maximal depletion 
of sulfate was observed at 12 hours, with the initial 
depletion evidenced as early as 6 hours. Using the maximal 
depletion time of 12 hours post treatment, a dose-dependent 
decrease in serum inorganic sulfate levels which levelled 
off at doses greater than 75 mg/kg i.p. was observed (Fig
8). The observed leveling off in serum sulfate depletion 
suggests that the quantity of serum inorganic sulfate that 
can be diverted to the conjugation of U-14,624 is limited. 
AS stated previously, Lin and Levy (1981) have demonstrated 
a similar phenomenon using acetaminophen in rats.
Bray et al (1952a and 1952b) have shown that when a dose 
of a drug capable of undergoing conjugation is given, 
initially sulfate conjugation tends to predominate and 
conjugation with glucuronic acid is minimal. But with 
increasing doses, sulfate conjugation becomes a less 
preponderant pathway and may become a zero order reaction. 
Conjugation with glucuronic acid then dominates since the 
source of glucuronic acid is glucose which is abundant in 
the body.
A significant difference was observed in the amounts of 
conjugated glucuronides between the absolute control and U-
14,624 treated rat urine. No significant difference was 
observed between the solvent control and U-14,624 treated
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rat urine, suggesting that the initial observed difference 
could be due to either artifact or stress resulting from the 
i.p. injection. However, this does not imply that U-14,624 
can not undergo conjugation with glucuronic acid. Increasing 
the size and/or utilizing a more sensitive testing procedure 
could give a more conclusive result.
The data presented in this paper demonstrates that U-
14,624 being a di- and tri- valent cation chelator, can 
indirectly or directly interact with several enzyme systems 
in experimental animals. Therefore, results of studies that 
employ U-14,624 should be interpreted with caution since the 
observed effect(s) could be due to the effects of U-14,624 
confounded by toxicity. Additionally, U-14,624 a lipophilic 
compound is biotransformed by sulfation and presumably 
glucuronidation, probably after aromatic hydroxylation.
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APPENDIX A 
ANALYTICAL PROCEDURES
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ESTIMATION OF PSEUDOCHOLINESTERASE ACTIVITY
Sigma diagnostic kit, procedure No. 420, Sigma chemical Co. 
St. Louis, MO.
R.a.ag.sat..s...L
Sodium Chloride solution (0.15 mol/1)
Nitrophenol solution (0.75 g/1)
Acetylcholine chloride solution (150 mg/ml)
Acetic acid solution (0.02 N)
Instruments:
IEC HN-S centrifuge 
Bausch and Lomb spectronic 600 
60^C water bath 
PCbçedux&i
1) 6-10 ml of blood were centrifuged twice at 4,000 rpm 
for 6 minutes and serum transferred to a clean tube for 
analysis.
2) 0.2 ml each of N a d  solution and serum were placed
• in two test-tubes, labelled blank and sample and were 
mixed by agitation.
3) The blank tube was placed in the 60^C water bath for 10 
minutes (to inactivate the enzyme) and cooled in cold 
tap water.
4) 3.0 ml of deionized water and 2.0 ml of the nitrophenol 
solution were added to the tubes. After all reagents 
have been brought to the same temperature, room
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temperature.
5) 0.20 ml of acetylcholine chloride solution was added to 
each tube and the exact time recorded. Tubes were mixed 
by shaking gently.
6) The tubes were allowed to stand on lab bench for 
exactly 30 minutes and the absorbance (A) was measured 
at 420nm, with water as a reference.
7) The difference between the blank and sample absorbance 
is then used to determine the serum
pseudocholinesterase activity in Rappaport units from 
the previously established calibration curve.
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DEIERMINAIXQN QF ANGIOTENSIN CONVERTING ENZYME (ACE)
ACTIVITY
Holmquist, B. , Bunning, P., and Riordan, J.P., A continuous 
spectrophotometric assay for Angiotensin Converting 
Enzyme (ACE), Anal Biochem, 95. 540, 1979.
Reagents :
ACE reagent (contains FAPGG 0.5 mmol/1)
ACE calibrators 
instruments :
IEC HN-S centrifuge
Bausch and Lomb spectronic 600 with constant temperature 
cuvette compartment.
37°C water bath 
Procedure:
1) 6-10 ml (for acute) or 2-3 ml (for chronic) blood 
samples were centrifuged twice at 4,000 rpm and serum 
transferred to a clear storage tube.
2) 1.0 ml of ACE reagent was placed in the assay test- 
tubes and brought to the reaction temperature, 37°C.
3) The ACE reagent was then transferred to a cuvette 
previously warmed up to 37°C, and 0.1 ml of the 
specimen (calibrator or sample) was added to the 
cuvette, which was mixed by inversion.
4) The cuvette was placed in the constant temperature 
compartment of the spectrophotometer for approximately 
5 minutes.
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5) Initial absorbance was taken and recorded at 340nm. 
Exactly, 5 minutes later the final absorbance read and 
recorded.
6) ACE activity was estimated by dividing the difference 
in absorbance after 5 minutes of the sample by that of 
the calibrator, multiplied by the given activity at 
37°C.
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DETERMINATION OF THYRQXTN LEVELS
TMCEDIA Assay, Microgenics, 2 380a Bisso Lane, Concord, CA 
R e a g e n t ? ;
Enzyme-Donor (ED) reagent with reconstitution buffer 
Enzyme-Acceptor (EA) reagent with reconstitution 
buffer
Calibrators (0.00, 10.00 & 20.00 ug/dl)
Instruments;
lEC HN-S centrifuge
Bausch and Lomb spectronic 600 with constant temperature 
cuvette compartment.
37°C water bath 
Procedure:
1) 0.03 ml of thyroxin source (control or sample), 0.075 
ml of distilled water and 0.80 ml of EA reagent were 
placed in a cuvette and mixed by inversion.
2) The mixture was incubated in the constant temperature 
cuvette compartment of the spectrophotometer at 37°C 
for 5 minutes.
3) 0.06 ml of ED reagent and 0.075 ml of distilled water 
were added to the cuvette, and mixed by inversion.
4) The cuvette was placed in the constant temperature 
compartment and initial absorbance read and recorded at 
420nm, using distilled water as a reference. At exactly
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6 minutes later, the final absorbance was read and 
recorded.
5) The difference between the final and initial absorbance 
were calculated.
6) levels was estimated by subtracting the previously 
calculated differences in absorbance for the sample and 
the control (0.00 ug/dl). This was then multiplied by 
the inverse slope of the previously established 
standard curve to obtain an estimate of the T^ levels.
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ESTIMATION OF S E R U M I N ORGANIC SULFATE LEVELS
Krijshed, K. R. , Frankena, H . , Scholtens, E . , Zweens, J . , 
and Mulder, G. J., Absorption, serum levels and urinary 
excretion of inorganic sulfate after oral administration 
of sodium sulfate in the conscious rat, Biochemica et 
Biophysica A c t a . 59 6 . 492, 1979.
Reagants-L
Trichloroacetic acid (TCA)
Barium chloride reagent (20.0 gm BaClg and 10 gm dextran 
in 1 liter of distilled water).
Instruments:
IEC HN-S centrifuge 
Bausch and Lomb spectronic 600 
Procedure:
1) 6-10 ml blood samples were centrifuged twice at 4,000
rpm for 6 minutes.
2) 1.5 to 2.0 ml of serum was transferred to 15 ml glass 
test-tubes and 6 to 8 ml TCA added to it and mixed by 
vortexing.
3) The tubes were allowed to stand for 10 minutes at room 
temperature, after which it was centrifuged at 4,000 
rpm for 5 minutes.
4) 2.0 ml of the supernatant was transferred to a clean 
test-tube and 0.5ml of BaClg reagent added to the 
tubes, and the time was recorded.
5) At precisely 35 minutes later, the absorbance was read
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at 460nm with distilled water as reference.
6) Serum inorganic sulfate (mg/ml) was estimated by
multiplying the absorbance reading by the inverse slope 
of the standard curve and dilution factor.
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ANALYSIS OF CONJUGATED GLUCURONIDES
Yuki, Hidetak and Fishman, William H . , Biochem. Biophys 
ACta, âa, 576, 1963.
Reagents;
Carbonate buffer (8.4 gm NaHCOg and 36.0 gm NaCOg in 1 
liter distilled water, adjusted to pH 10.10)
Iodine solution (1 N)
Sodium bisulfite (l M)
Acetic acid (10 N)
Mercury chloride (0.25 M)
Carbazole reagent (0.125% carbazole in absolute ethanol) 
Sulfuric acid reagent (5 ml 1 M sodium tetraborate added 
to 195 ml analytical grade sulfuric acid)
Alconox solution (0.1%)
Instruments;.
Boiling water bath 
lEC HN-S centrifuge 
Ice bath
Room temperature water bath 
Duraier air pump 
Bausch and Lomb spectronic 600 
;
1) 3.0 ml of the specimen (standard glucuronic acid
solution or 50-fold diluted urine), 1 ml each 
of carbonate buffer and iodine solution were placed in
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a 15 ml glass centrifuge tubes.
2) The tubes were mixed by vortexing and allowed to stand 
for 20 minutes at room temperature.
3). 0.10 ml of sodium bisulfite and 0.20 ml of acetic acid 
were added to the mixture. The tubes were vortexed to 
release COg.
4 ) 0.7 ml of HgClg was added to mixture test-tubes and
allowed to stand for 10 minutes at room temperature. To 
accelerate reaction the tubes were heated for 3 minutes 
in boiling water bath.
5) 0.05 ml of Alconox solution was added along the inner 
side of the tube wall to precipitate any small 
particles of Hgig afloat on the surface.
6) The tubes were centrifuged at 4,000 rpm for 10 minutes 
to remove the precipitate.
7) The top 0.5-1.0 ml of the supernatant was carefully 
removed, without disturbing the precipitate with a 
duraier air pump to further eliminate any contaminates 
afloat.
8) 1.0 ml of the remaining supernatant was transferred to 
a clean tube and 6.0 ml of previously ice cooled 
sulfuric acid reagent added to it and mixed vigorously 
by vortexing.
9) The mixture was covered with a glass marble, heated in 
boiling water bath for 20 minutes and cooled for 5
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minutes in the room temperature water bath.
10) 0.2 ml of carbazole reagent was added to the cooled
tubes and mixed vigorously by vortexing.
11) The tubes were heated in boiling water bath for 10 
minutes and cooled in the room temperature bath. The 
absorbance, A was read and recorded at 540nm with 
distilled water as a reference.
12) The amount of conjugated glucuronides present in the 
urine per 24 hours was estimated by multiplying the 
absorbance by the inverse slope of the standard curve 
and the 50-fold dilution.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
